25.60

1.83% 0.46

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $25.60, with a volume of 1.16M. It is up +1.83% in the last 24 hours and down -12.75% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$25.14

Open:

$25.6

24h Volume:

1.16M

Relative Volume:

1.75

Market Cap:

$1.79B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-6.7725

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

+17.06%

1M Performance:

-12.75%

6M Performance:

-4.33%

1Y Performance:

+16.84%

1-Day Range:

$25.25

$26.20

1-Week Range:

$21.97

$26.20

52-Week Range:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	25.60	1.79B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

Jan 20, 2025

Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $46.83 - MarketBeat

Jan 20, 2025

Jan 19, 2025

H.C. Wainwright maintains buy on Akero stock - MSN

Jan 19, 2025

Jan 18, 2025

HC Wainwright Reiterates “Buy” Rating for Akero Therapeutics (NASDAQ:AKRO) - Defense World

Jan 18, 2025

Jan 17, 2025

Akero Therapeutics (NASDAQ:AKRO) Trading Up 8.4%Time to Buy? - MarketBeat

Jan 17, 2025

H.C. Wainwright maintains buy on Akero stock By Investing.com - Investing.com Canada

Jan 17, 2025

Akero Therapeutics (NASDAQ:AKRO) Given Buy Rating at HC Wainwright - MarketBeat

Jan 17, 2025

Jan 13, 2025

Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 8.6%Should You Sell? - MarketBeat

Jan 13, 2025

(AKRO) Trading Report - Stock Traders Daily

Jan 13, 2025

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin in Patients with Non-Invasively Diagnosed Mash or MASLD - Marketscreener.com

Jan 13, 2025

Akero Therapeutics Completes Phase 3 SYNCHRONY Enrollment for Groundbreaking MASH Treatment - StockTitan

Jan 13, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - AccessWire

Jan 13, 2025

Jan 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by JPMorgan Chase & Co. - Defense World

Jan 12, 2025

JPMorgan Chase & Co. Sells 54,221 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jan 12, 2025

Jan 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - AccessWire

Jan 11, 2025

Jan 09, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - AccessWire

Jan 09, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - AccessWire

Jan 09, 2025

Jan 08, 2025

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail

Jan 08, 2025

Jan 07, 2025

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 07, 2025